Lidocaïne-d6

Lidocaine-d6 (Lignocaine-d6) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

1215823-29-2

Lignocaine-d6

12352005

Apoptosis; ERK; Isotope-Labeled Compounds; MEK; NF-κB; Sodium Channel

Apoptosis; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; Others; Stem Cell/Wnt

Cancer-Kinase/protease

Cancer; Cardiovascular Disease

O=C(NC1=C(C([2H])([2H])[2H])C=CC=C1C([2H])([2H])[2H])CN(CC)CC

C14H16D6N2O

240.37

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582 (Pt 1) :11.|[3]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19 (1) :233.|[4]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113 (1) :31-6.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0185S2/

Isotope-Labeled Compounds

No Development Reported